IBD — primarily Crohn’s disease and ulcerative colitis — has no known cause, though many believe it occurs when microbes within the intestine trigger an immune response in predisposed individuals.
The EU-funded project, titled “IBD: Proteases Offer New Targets for Drug Discover,” is examining matrix metalloproteases enzymes, which break down other proteins. The researchers’ new insight could help focus treatment studies on various inhibitors or agonists of digestive bacterial proteases.
More Articles on Gastroenterology:
University Hospital in London Hosting Live Endoscopy Course
Irritable Bowel Syndrome Drug Eluxadoline Could Relieve IBS Symptoms
Mailed Invitations May Increase Screenings for Noninvasive Tests
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
